This page contains recent news articles, when available, and an overview of but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Background information on

Array BioPharma Advances p38 / Tie2 Inhibitor, ARRY-614, into ...  -  25 Mar 2008
Trading Markets (press release),..."We believe the dual inhibition of p38 and Tie2 may produce additive and/or synergistic effects with other therapies in treating multiple myeloma and other

Treatment's side effects may include bankruptcy  -  25 Mar 2008
Houston Chronicle,...retiree Helen Geiger of Whiting, NJ, paid for a premium plan and put it to good use when she was diagnosed with multiple myeloma, a blood cancer.

Orphan News :: Treatment & Health  -  25 Mar 2008
Checkbiotech.org (press release),In Germany,RIBOMUSTIN is indicated as a single-agent or in combination with otheranti-cancer agents for indolent NHL, multiple myeloma, and CLL.

Robert M. Figlio, 69, criminologist, author  -  25 Mar 2008
Philadelphia Inquirer,...and crime-prevention consultant to industry and government, died of multiple myeloma on March 15 at the Hospital of the University of Pennsylvania.

Agricultural Economics professor Bruce Gardner, 67, is dead  -  25 Mar 2008
Diamondback Online,...and advised three US presidents on the subject, died March 14 of multiple myeloma at the University of Maryland Medical Center in Baltimore. He was 67.

Understanding multiple myeloma  -  Mar 8, 2008
Malaysia Star,By Dr JV SANGKAR Multiple myeloma is a type of cancer of plasma cells, which are immune system cells in bone marrow. MULTIPLE myeloma (also known as myeloma

New Biological Agents Added to Treatment Algorithm for Multiple ...  -  Mar 11, 2008
DG NewsLenalidomide, an analog of thalidomide, which acts as an immune modulator, reducing cytokine proliferation that occurs in multiple myeloma.

Combination Therapy Effective Against Multiple Myeloma  -  Mar 14, 2008
Cancerpage.com,...lenalidomide and dexamethasone is successful in most patients with newly diagnosed symptomatic multiple myeloma, according to New York-based researchers

Acceleron provides hope for multiple myeloma  -  Mar 7, 2008
India New England,Multiple Myeloma Research Foundation to support the research and development of ACE-011, a bone forming agent, for the treatment of multiple myeloma.

Doctor Shares Story Of Living With Multiple Myeloma  -  Mar 7, 2008
KSDK,Here's a closer look at a cancer of the blood called multiple myeloma. Multiple Myeloma, or MM, is a cancer of immune system cells that make antibodies in

Immunomedics, Inc. (IMMU)'s Milatuzumab receives FDA orphan drug ...  -  Mar 19, 2008
Checkbiotech.org (press release),The designation allows the Company to have a seven-year market exclusivity for milatuzumab in multiple myeloma upon final approval by the FDA.

Multiple myeloma group to meet  -  Mar 1, 2008
Cherry Hill Courier Post,The Philadelphia Multiple Myeloma Networking Group meets from 1:30 to 3:30 pm March 8 at the Ralston House, 3615 Chestnut St., Philadelphia.

Part two: Living with Multiple Myeloma  -  Feb 26, 2008
Petoskey News-Review,By Marci Singer News-Review Staff Writer For Petoskey residents, Bob (right) and Marty McCullough, multiple myeloma is personal. Diagnosed in 2003, Bob is

Celgene's Cancer Drug Is Key  -  Mar 20, 2008
CNNMoney.comBoth drugs aim to make multiple myeloma a manageable disease and increase life expectancy. Multiple myeloma is a type of cancer with a high mortality rate.

Millennium reports promising results for blood cancer drug  -  Mar 13, 2008
Boston Globe,In a clinical trial, a combination of Velcade, melphalan, and prednisone was used to treat patients with newly diagnosed multiple myeloma who were

Cancer woman deported to Ghana dies  -  Mar 20, 2008
Telegraph.co.uk,Mrs Sumani, who suffered from multiple myeloma, died at 4pm yesterday at Korle-Bu hospital in Accra. Hours earlier friends and family found doctors in

Mayo Clinic cancer model to speed up drug research  -  Mar 16, 2008
Arizona Republic,Mayo Clinic Arizona scientists recently completed research that may speed development of new treatments for multiple myeloma, a common type of blood cancer.

Myeloma group slates 'Laugh for Life' fundraiser  -  Mar 4, 2008
St.Louis Jewishlight.com,The event will also celebrate the progress being made in fighting multiple myeloma by honoring Ravi Vij, MD Vij is at Washington University and is the

Publication of Clinical Results Underscores Velcade (Bortezomib ...  -  Mar 13, 2008
PharmaLive.com (press release),Multiple myeloma is the second most common hematological malignancy and although the disease is predominantly a cancer of the elderly (the median age of

Immunomedics gets FDA orphan drug designation for milatuzumab  -  Mar 18, 2008
CNNMoney.comInc. Tuesday said the Food and Drug Administration has granted orphan drug designation to milatuzumab for the treatment of multiple myeloma.

Disco will live again at charity fundraiser  -  Mar 20, 2008
East Brunswick Sentinel,Goldstein's mother, Jennifer Basile of the Monmouth Junction section of South Brunswick, is suffering from multiple myeloma, a cancer of the plasma cell,

EU body warns against Velcade use in some patients  -  Mar 20, 2008
ReutersVelcade is approved to treat patients with multiple myeloma who have received at least one prior therapy. (Reporting by Ben Hirschler; editing by Rory

Kosan Biosciences Incorporated Q4 2007 Earnings Call Transcript  -  Mar 19, 2008
Seeking Alpha,Multiple myeloma, we’re positioning tanespimycin to potentially capture a significant share of the second-line market.

Anti-Cancer Drug CYT997 Update  -  Mar 12, 2008
Sydney Morning Herald,The potential activity of this compound in multiple myeloma extends for CYT997 in multiple myeloma within three months. Orphan drug designation gives a 2.

Bay State firms could get boost from cancer drugs  -  Mar 14, 2008
Boston Globe,Velcade has already been approved in the United States as a treatment for multiple myeloma patients who have received at least one prior therapy;

Cancer victim deported to Ghana dies  -  Mar 19, 2008
Times Online,Multiple myeloma is a cancer that affects plasma cells in the bone marrow. Up to 20000 people are living with the condition at any one time in Britain.

Celgene CEO lays out firm's game plan  -  Mar 14, 2008
The Star-Ledger - NJ.com,The company will spend the next 90 days working on the integration of Pharmion, which returns the European rights to the multiple myeloma treatment Thalomid

Piper Jaffray Upgrade Boosts Millennium  -  Mar 13, 2008
Forbes,Velcade is currently approved in the US to treat multiple myeloma patients who have taken at least one prior treatment. The Food and Drug Administration is

Dinner to help family fighting cancer  -  Mar 16, 2008
Connecticut Post,Schmidheini, 32, was diagnosed with multiple myeloma, a cancer of the plasma cell. According to the Multiple Myeloma Research Foundation, excessive numbers

The Globetrotter  -  Mar 23, 2008
Boston Globe,Former vice presidential candidate Geraldine Ferraro will be in Boston on May 2 to speak about her battle with multiple myeloma, an incurable blood cancer.

Geron Corporation Q4 2007 Earnings Call Transcript  -  Mar 17, 2008
Seeking Alpha,...and that's studying the drug as single agent in patients with multiple myeloma who have failed at least two prior courses of chemotherapy.

A Fuller Medicine Chest  -  Feb 25, 2008
Smartmoney.comBut 40 years later, thalidomide is again a blockbuster — treating multiple myeloma and other cancers that attack blood and bones. Two years ago, Celgene,

Publication of Clinical Results Underscores VELCADE(R) (Bortezomib ...  -  Mar 13, 2008
SunHerald.com,...melphalan and prednisone (VcMP) in newly diagnosed multiple myeloma patients, who were ineligible for stem cell transplantation.

Cancer patient credits recovery to hands of God  -  Mar 14, 2008
Herald & Review,About two years ago, Al Hawkins Jr. was lying in a bed at Decatur Memorial Hospital suffering from multiple myeloma, his family and pastor surrounding him

Oncolytics Biotech Inc. Collaborators to Present Reovirus Research ...  -  Mar 13, 2008
CNW Telbec (Communiqués de presse),The first abstract, entitled "Targeting Multiple Myeloma with Oncolytic Viral Therapy" covers preclinical work using reovirus as a purging agent during

Former Isle chief 'Jack' Gallaway dies  -  Mar 20, 2008
Biloxi Sun Herald,Gallaway had been battling multiple myeloma cancer for four years, said Joyce Hart, his assistant from 1996 until his retirement in 2003. "He was dynamic.

Proteolix Names Matthew Ferguson to Newly-Created Position of ...  -  Feb 26, 2008
FOXBusinessCarfilzomib is currently in Phase II clinical studies to evaluate its safety and efficacy in multiple myeloma, lymphoma and solid tumor malignancies.

Analyst Sees Velcade Sales Doubling  -  Feb 25, 2008
CNNMoney.comIn December, Millenium shares surged after a late-stage study of multiple myeloma drug Velcade quadrupled complete remission rates when used as an initial

Biotest achieves major milestones in the development of ...  -  Mar 11, 2008
Ad-Hoc-News (Pressemitteilung),The FDA granted monoclonal antibody, BT-062, Orphan Drug designation for the indication multiple myeloma. In principle, this grants market exclusivity in

Acceleron Pharma and Celgene Corporation Receive Hart-Scott-Rodino ...  -  Mar 24, 2008
PR-Inside.com (Pressemitteilung),ACE-011 is currently in a Phase 1b study and Acceleron expects to begin a Phase 2a study in multiple myeloma in the middle of 2008. Acceleron is a privately

Geron Corporation Reports Fourth Quarter and Annual 2007 Financial ...  -  Feb 27, 2008
WELT ONLINE,Initiated clinical trial of GRN163L in patients with multiple myeloma. The primary objective of the Phase I study is to determine the safety and maximum

Acceleron Pharma and Celgene Corporation Receive Hart-Scott-Rodino ...  -  Mar 24, 2008
Business Wire (press release),ACE-011 is currently in a Phase 1b study and Acceleron expects to begin a Phase 2a study in multiple myeloma in the middle of 2008. Acceleron is a privately

Immunogen Stock Rises on Drug Filing  -  Mar 12, 2008
CNNMoney.comThe compound is designed to treat multiple myeloma, a blood disease, and other cancers. Shares of Immunogen Inc., which is based in Cambridge, Massachusetts

Kosan axes staffers (again), scouts for partners  -  Mar 19, 2008
FierceBiotech,Kosan will circle the wagons around its lead clinical programs: tanespimycin in multiple myeloma and in metastatic breast cancer, and epothilone KOS-1584 in

Millennium Pharma Reports Higher Complete Remission Rates From ...  -  Mar 13, 2008
Trading Markets (press release),...of the Phase I/II clinical trial of the combination therapy VELCADE, melphalan and prednisone, or VcMP, in newly diagnosed multiple myeloma patients.

Cytopia Starts Dosing Patients In First Suite Of Phase II Clinical ...  -  Mar 12, 2008
Trading Markets (press release),Cytopia commenced dosing in its first Phase II efficacy study in patients with relapsed or refractory multiple myeloma in January 2008.

Anti-Cancer Drug CYT997 Update  -  Mar 12, 2008
PR Newswire (press release),Phase II trial in multiple myeloma Cytopia commenced dosing in its first Phase II efficacy study in patients with relapsed or refractory multiple myeloma in

Reunion 2008: A beer to help fight disease  -  Mar 5, 2008
Inside Bay Area,All proceeds go to the Institute for Myeloma & Bone Cancer Research, a national nonprofit dedicated to fighting multiple myeloma and similar diseases.

Continuing Diane Holum's legacy  -  Mar 23, 2008
Marshall Independent,On Wednesday, Holum died after a fight with multiple myeloma, Hinz said. She had been in hospice in Willmar for a little more than 10 days.

Cephalon Could Turn Tide If Cancer Drug Is Approved  -  Mar 19, 2008
Wall Street Journal...against other lymphomas; as well as for multiple myeloma, a cancer that begins in blood cells; and in solid tumors, such as in lung and breast cancer.

Search the web for more resources on

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.